The Right Price

A Value-Based Prescription for Drug Costs

AvPeter J. Neumann,Joshua T. Cohen

Häftad, Engelska, 2021

771 kr

. Fri frakt över 249 kr.

Fler format och utgåvor

Inbunden

1 502 kr

Beskrivning

The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify.The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States.With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

Produktinformation

Utgivningsdatum:2021-10-12
Mått:157 x 235 x 17 mm
Vikt:400 g
Format:Häftad
Språk:Engelska
Antal sidor:272
Förlag:OUP USA
ISBN:9780197512876

Utforska kategorier

Farmakologi inom Medicin
Miljöekonomi inom Ekonomi och Ledarskap
Statsvetenskap och politisk teori inom Samhälle och politik

Mer om författaren

Peter J. Neumann, ScD, is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. Dr. Neumann is also a member of the editorial advisory board of Health Affairs and the health policy advisory board for the Congressional Budget Office.Joshua T. Cohen, PhD, is Deputy Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Research Associate Professor of Medicine at Tufts University School of Medicine.Daniel A. Ollendorf, PhD, is Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Research Assistant Professor of Medicine at Tufts University School of Medicine. Prior to joining CEVR, he spent ten years as the Chief Scientific Officer at the Institute for Clinical and Economic Review (ICER). Dr. Ollendorf currently serves as a non-resident Fellow at the Center for Global Development, and as Chair of the Health Technology Assessment International (HTAi) Global Policy Forum.

Recensioner i media

This is a timely book. Highly recommended. All readers.

Innehållsförteckning

Acknowledgments Preface PART 1: THE ECONOMICS OF PRESCRIPTION DRUGS Chapter 1: Introduction Chapter 2: The prescription drug market Chapter 3: Proposed solutions for rising drug prices Chapter 4: Measuring the value of prescription drugs PART 2: EXPERIENCES MEASURING A DRUG'S VALUE IN THE US AND ABROAD Chapter 5: Measuring drug value: Whose job is it anyway? Chapter 6: Institute for Clinical and Economic Review (ICER) Chapter 7: Other US value assessment frameworks Chapter 8: Do drugs for special populations warrant higher prices? PART 3: GETTING TO VALUE-BASED PRICING FOR DRUGS Chapter 9: Improving value measurement Chapter 10: Aligning prices with value Chapter 11: The path forward Index